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Control of Glycolytic Flux by AMPK and 
p53-Mediated Signaling Pathways in Tumor 
Cells Adapted to Grow at Low pH
Introduction
Tumor cells grow in nutrient and oxygen deprived microenvironments 
and adapt to the suboptimal growth conditions by altering metabolic 
pathways. This adaptation process characteristically results in a tumor 
phenotype that displays anaerobic glycolysis, chronic acidification 
and aggressive tumor characteristics. Understanding the tumor cell 
reaction to the microenvironment is a critical factor in predicting the 
tumor response to hyperthermia. The glucose regulatory molecule, 
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase Isoform-3 
(PFKFB3), is a bifunctional enzyme central to glycolytic flux and 
downstream of the metabolic stress sensor AMP-activated protein 
kinase (AMPK), which has been shown to activate an isoform of 
Phosphofructokinase (PFK-2).
Results
As hypothesized, our results demonstrated that exposure to chronic 
low pH induced AMPK activation which resulted in the upregulation 
of PFKFB3 and p53, and the downregulation of mammalian Target-
Of-Rapamycin (mTOR) in two tumor cell lines, DB-1 human 
melanoma and U87 human glioma. Conversely, inhibition of 
AMPK resulted in downregulation of PFKFB3 and inhibition of 
glycolysis. When PFKFB3 was over-expressed in DB-1 melanoma, it 
induced a high rate of glycolysis and inhibited oxygen consumption. 
By contrast, cells adapted to growth at low pH did not display an 
increased rate of glycolysis after PFKFB3 induction because the level 
of the TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) 
was increased. Low pH adapted cells also were resistant to apoptosis, 
despite upregulation of p53. This may be partially explained by the 
induction of anti-apoptotic proteins and TIGAR’s ability to reduce 
lactate production.
Conclusion
These results indicate that growth at tumor-like low pH activates 
AMPK and induces a high glycolytic and apoptotic potential that is 
countered by TIGAR and anti-apoptotic proteins, respectively. The 
control of glycolysis can thus minimize acidification and further 
protect tumor cells from death. These metabolic pathways in response 
to the microenvironment need to be incorporated in hyperthermia 
treatment strategies. 
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